Given our increasingly aging society, the number of patients with malignant urogenital diseases (e.g., prostate cancer, urothelial cancer, renal cell carcinoma) is increasing. Meanwhile, overdiagnosis and overtreatment are also problems, especially given the morbidities of many of the treatments available such as radical prostatectomy or radical cystectomy.
Urinary biomarkers of urological malignancies
A narrative review of urinary phospholipids: from biochemical aspect towards clinical application
Narrative review of urinary glycan biomarkers in prostate cancer
Toward urinary cell-free DNA-based treatment of urothelial carcinoma: a narrative review
Urinary extracellular vesicles: a rising star in bladder cancer management
Extracellular vesicles in prostate cancer: a narrative review
UroVysion fluorescence in situ hybridization in urothelial carcinoma: a narrative review and future perspectives
MiR-30b-3p and miR-126-3p of urinary extracellular vesicles could be new biomarkers for prostate cancer
The series “Urinary Biomarkers of Urothelial Malignancies” was commissioned by the editorial office, Translational Andrology and Urology without any sponsorship or funding. Kazutoshi Fujita is serving as the unpaid Guest Editor for the series.